Skip to content


Dermatology icon

Dermatology at Mass General Brigham is complex, collaborative, and cutting-edge. From safe, effective treatments for severe acne to novel therapeutics for rare skin diseases, discoveries emerging from the Brigham and Women’s Hospital (BWH) and Massachusetts General Hospital (MGH) are leading the field in innovation.

The Dermatology departments drive investment in Mass General Brigham-derived therapies, devices, and procedures to expedite the pathway from discovery to commercial development. This Market Sector encompasses research and clinical capabilities at the BWH and MGH that cover the entire spectrum of dermatology, including autoimmune disorders, melanoma and other cancers, plastic surgery, burn care, and treatment for both common and rare conditions of the skin, nails, and hair.

In this space, the Wellman Center for Photomedicine remains a leader in the field. During the last 10 years, Wellman’s products have produced more than $7 Billion in sales.

Cross Disciplinary Initiatives

Our investigators are among the top in their field; their out-of-the-box approaches to dermatological science have illuminated unexpected connections between skin conditions like psoriasis and cardiovascular diseases, depression, and cancer.

Brigham and Women's Hospital
BWH Department of Dermatology
BWH Laser and Skin Health Center
Cutaneous Oncology Disease Program
Human Skin Disease Research Center
Mohs and Dermatologic Surgery Center
Specialized Program of Research Excellence (SPORE) in Skin Cancer

Massachusetts General Hospital
MGH Department of Dermatology
Clinical Unit for Research Trials in Skin (CURTIS)
Cutaneous Biology Research Center
Wellman Center for Photomedicine


Partners GRAPHICS (Brand Icons) 200917_1523 INNOVATION SITE 96-40


In the News

Scientists find possible topical treatment for skin lesions

February 1, 2016

BOSTON, Jan. 29 (UPI) — Researchers at Harvard University found that blocking specific signaling enzymes that contribute to common benign skin lesions called seborrheic keratoses, or SKs, cause them die, according to a new study. The researchers, who work at Massachusetts General Hospital, were investigating why the lesions, which have genetic similarities to cancer, grow…

Empirical Treatment More Cost-Effective for Onychomycosis

January 8, 2016

For patients with suspected onychomycosis, empirical treatment with terbinafine is more cost-effective than confirmatory testing, according to a study published online Dec. 23 in JAMA Dermatology. Anar Mikailov, M.D., from Brigham and Women’s Hospital in Boston, and colleagues examined the cost and potential harm associated with three approaches to onychomycosis evaluation before oral terbinafine or…

Dieter Manstein MD, PhD: Innovative Procedures Get Under Your Skin

December 1, 2013

A profile of Dieter Manstein, MD, PhD, and his great achievements in Dermatology: fractional photothermolysis and selective Cryolipolysis®. Dieter Manstein, MD, PhD turned a two-year research project into a career of developing major dermatology innovations to treat scars, skin aging, and noninvasively remove fat. In November of 1998, he immigrated to Boston, from Germany, where…